(NASDAQ: PHVS) Pharvaris Nv's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Pharvaris Nv's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PHVS's revenue for 2026 to be $637,925,809, with the lowest PHVS revenue forecast at $637,925,809, and the highest PHVS revenue forecast at $637,925,809. On average, 3 Wall Street analysts forecast PHVS's revenue for 2027 to be $3,941,479,887, with the lowest PHVS revenue forecast at $1,026,684,790, and the highest PHVS revenue forecast at $5,669,333,834.
In 2028, PHVS is forecast to generate $12,865,099,981 in revenue, with the lowest revenue forecast at $9,574,053,185 and the highest revenue forecast at $16,156,146,776.